Akoya Reports First Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance
Q1 2022 revenue $16.9 million, 38% growth over prior year period
Raising FY 2022 revenue guidance range to $70-73 million
MARLBOROUGH, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2022.
“Akoya remains on an exciting trajectory, delivering record revenue and system placements in the first quarter,” said Brian McKelligon, Chief Executive Officer, Akoya Biosciences. “This quarter was highlighted by the commercial launch of the PhenoCycler-Fusion System and showcasing powerful new data of our 100+ plex antibody panels as well as the new universal chemistry capabilities at the recent AACR meeting. We continued to execute on all segments of the business and are confident in our updated full year revenue guidance.”
First Quarter 2022 Financial Highlights
- Total revenue was $16.9 million in the first quarter of 2022, compared to $12.2 million in the prior year period; an increase of 38%.
- Product revenue was $13.3 million in the first quarter of 2022, compared to $10.0 million in the prior year period; an increase of 34%; within product revenue, reagent revenue was $4.6 million for the quarter, versus $2.5 million in the prior year period; an increase of 82%.
- Services and other revenue totaled $3.6 million in the first quarter of 2022, compared to $2.2 million in the prior year period; an increase of 58%.
- Gross profit was $10.1 million in the first quarter of 2022, compared to $7.4 million in the prior year period; an increase of 36%; gross profit margin was 60% in the first quarter of 2022.
- 51 instruments were sold in the first quarter of 2022; 14 PhenoCyclers, 37 PhenoImagers (which includes Fusion and HT).
- Instrument installed base of 748 as of March 31, 2022; 196 PhenoCyclers, 552 PhenoImagers (of which 28 are the new Fusion instruments).
- Combined-unit PhenoCycler-Fusion installed base of 23 as of March 31, 2022.
First Quarter 2022 Business Highlights
- As of March 31, 2022, there have been 531 total publications featuring Akoya’s platforms; 112% growth from 251 total publications as of March 31, 2021.
- Appointment of Dr. Ehab El-Gabry, M.D. as Akoya’s new Chief Medical Officer, who brings over 20 years of leadership experience in pathology and IVD development that are critical for Akoya’s vision of advancing spatial phenotyping in precision medicine and cancer care.
- Showcased new data for a panel of 100+ protein markers for deep spatial phenotyping at single-cell resolution across an entire tissue sample at AACR.
- Previewed the new universal chemistry to enable accelerated validation of biomarkers discovered using deep spatial phenotyping at AACR.
- Launched world tour for PhenoCycler-Fusion across 29 cities in North America, Europe, and Asia-Pacific; please visit https://www.akoyabio.com/fusion-tour/ for a full list of the world tour cities and dates to experience the PhenoCycler-Fusion at a city near you.
- $94 million of cash and cash equivalents as of March 31, 2022, well capitalized to deliver on our existing strategic plan.
2022 Outlook
The company, based on its updated plans and initiatives, is raising its full year 2022 revenue guidance range to $70-73 million.
Webcast and Conference Call Details
Akoya will host a conference call today, May 5, 2022, at 5:00 p.m. Eastern Time to discuss its first quarter 2022 financial results. The dial-in numbers are (833) 562-0146 for domestic callers or (661) 567-1226 for international callers, followed by Conference ID: 7363649. A live webcast of the conference call will be available on the “Investors” section of the Company's website at https://investors.akoyabio.com/. The webcast will be archived on the website following the completion of the call for three months.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including expectations regarding our ability to market and sell our PhenoCycler and PhenoImager platforms and increase awareness of spatial biology technology, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
Akoya Biosciences, Inc.
investors@akoyabio.com
Media Contact:
Christine Quern
Akoya Biosciences, Inc.
cquern@akoyabio.com
AKOYA BIOSCIENCES, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets (unaudited)
(in thousands)
| March 31, 2022 | December 31, 2021 | |||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 93,938 | $ | 113,079 | ||
| Accounts receivable, net | 11,314 | 9,444 | ||||
| Inventories, net | 11,373 | 9,014 | ||||
| Prepaid expenses and other current assets | 9,841 | 9,277 | ||||
| Total current assets | 126,466 | 140,814 | ||||
| Property and equipment, net | 7,588 | 7,487 | ||||
| Demo inventory, net | 2,225 | 2,548 | ||||
| Intangible assets, net | 20,960 | 21,150 | ||||
| Goodwill | 18,262 | 18,262 | ||||
| Operating lease right of use assets, net | 9,937 | — | ||||
| Financing lease right of use assets, net | 1,047 | — | ||||
| Other non-current assets | 643 | 646 | ||||
| Total assets | $ | 187,128 | $ | 190,907 | ||
| Liabilities and Stockholders’ Equity | ||||||
| Current liabilities | ||||||
| Accounts payable, accrued expenses and other current assets | $ | 23,656 | $ | 23,198 | ||
| Current portion of operating lease liabilities | 2,805 | — | ||||
| Current portion of financing lease liabilities | 383 | — | ||||
| Deferred revenue | 4,892 | 4,484 | ||||
| Total current liabilities | 31,736 | 27,682 | ||||
| Deferred revenue, net of current portion | 1,519 | 1,330 | ||||
| Long-term debt, net | 32,576 | 32,471 | ||||
| Contingent consideration liability, net of current portion | 6,755 | 7,850 | ||||
| Operating lease liabilities, net of current portion | 7,506 | — | ||||
| Financing lease liabilities, net of current portion | 448 | — | ||||
| Other long-term liabilities | 36 | 223 | ||||
| Total liabilities | 80,576 | 69,556 | ||||
| Total stockholders' equity | 106,552 | 121,351 | ||||
| Total liabilities and stockholders' equity | $ | 187,128 | $ | 190,907 | ||
AKOYA BIOSCIENCES, INC. AND SUBSIDIARY
Consolidated Statements of Operations (unaudited)
(in thousands, except share and per share amounts)
| Three months ended | ||||||||
| March 31, | March 31, | |||||||
| 2022 | 2021 | |||||||
| Revenue: | ||||||||
| Product revenue | $ | 13,343 | $ | 9,963 | ||||
| Service and other revenue | 3,551 | 2,249 | ||||||
| Total revenue | 16,894 | 12,212 | ||||||
| Cost of goods sold: | ||||||||
| Cost of product revenue | $ | 4,080 | $ | 3,607 | ||||
| Cost of service and other revenue | 2,718 | 1,200 | ||||||
| Total cost of goods sold | $ | 6,798 | $ | 4,807 | ||||
| Gross profit | $ | 10,096 | $ | 7,405 | ||||
| Operating expenses: | ||||||||
| Selling, general and administrative | 18,193 | 8,179 | ||||||
| Research and development | 5,714 | 3,192 | ||||||
| Change in fair value of contingent consideration | 200 | 426 | ||||||
| Depreciation and amortization | 1,543 | 1,009 | ||||||
| Total operating expenses | 25,650 | 12,806 | ||||||
| Loss from operations | (15,554 | ) | (5,401 | ) | ||||
| Other income (expense): | ||||||||
| Interest expense, net | (749 | ) | (751 | ) | ||||
| Change in fair value of warrant liability | — | (1,870 | ) | |||||
| Other expense, net | (74 | ) | (66 | ) | ||||
| Loss before benefit (provision) for income taxes | (16,377 | ) | (8,088 | ) | ||||
| Benefit (provision) for income taxes | (22 | ) | 6 | |||||
| Net loss | $ | (16,399 | ) | $ | (8,082 | ) | ||
| Dividends accrued on redeemable convertible preferred stock | — | (1,190 | ) | |||||
| Accretion of redeemable convertible preferred stock | — | (296 | ) | |||||
| Adjusted net loss attributable to common stockholders | (16,399 | ) | (9,568 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.44 | ) | $ | (3.54 | ) | ||
| Weighted-average shares outstanding, basic and diluted | 37,464,496 | 2,706,133 | ||||||
